The critical role of interleukin-23 in spondyloarthropathy

Research output: Contribution to journalArticle

Colleges, School and Institutes

External organisations

  • Merck Research Laboratories, 901 California Avenue, Palo Alto, CA 94304, USA

Abstract

The spondyloarthropathies represent highly enigmatic conditions and although their clinical features, anatomical distribution of disease and genetic predisposing factors have been known for some time, a unified concept of the basic pathobiology underlying these illnesses has remained undefined. Recently progress has been made because numerous independent studies have converged upon IL-23 as a central cytokine in spondyloarthropathy and the mechanism and sites of action of this cytokine have now become much clearer. These findings enable the rational design of therapeutic strategies which it is hoped will profoundly modify the progression of these diseases. We will review the anatomical sites affected and the evidence for the importance of IL-23 in these conditions, before drawing these lines of investigation together to propose a model for the unified understanding of spondyloarthropathy.

Details

Original languageEnglish
Pages (from-to)38-43
JournalMolecular immunology
Volume57
Issue number1
Early online date1 Aug 2013
Publication statusPublished - Jan 2014

Keywords

  • Enthesitis, Spondyloarthropathy, Interleukin-23, T lymphocytes